Related references
Note: Only part of the references are listed.The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition
S. Loi et al.
ANNALS OF ONCOLOGY (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Low pretreatment lymphocyte/monocyte ratio is associated with the better efficacy of neoadjuvant chemotherapy in breast cancer patients
Yang Peng et al.
CANCER BIOLOGY & THERAPY (2020)
The dynamic change of neutrophil to lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients
Jiaqiang Dan et al.
BREAST CANCER (2020)
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth A. Mittendorf et al.
LANCET (2020)
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
Leisha A Emens et al.
LANCET ONCOLOGY (2020)
Association between levels of tumor-infiltrating lymphocytes in different subtypes of primary breast tumors and prognostic outcomes: a meta-analysis
Lin He et al.
BMC WOMENS HEALTH (2020)
Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC
Chiara Massa et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Prognostic Factors and Tumor Infiltrating Lymphocytes in Triple Negative Breast Cancer
Ozgecan Dulgar et al.
EUROPEAN JOURNAL OF BREAST HEALTH (2020)
Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis
Yutian Zou et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial
Signe Korsgaard Skriver et al.
BREAST CANCER RESEARCH (2020)
Predictive and prognostic value of circulating blood lymphocyte subsets in metastatic breast cancer
Jian Yang et al.
CANCER MEDICINE (2019)
NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival
Aura Muntasell et al.
CLINICAL CANCER RESEARCH (2019)
Cancer Inflammation and Cytokines
Maria Rosaria Galdiero et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2018)
Human T Cell Development, Localization, and Function throughout Life
Brahma V. Kumar et al.
IMMUNITY (2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert et al.
LANCET ONCOLOGY (2018)
Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies
Tessa G. Steenbruggen et al.
DRUGS (2017)
Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer
G. Pruneri et al.
ANNALS OF ONCOLOGY (2016)
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Peter Savas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes A Systematic Review
Sasha E. Stanton et al.
JAMA ONCOLOGY (2016)
Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer
Sidra Nawaz et al.
MODERN PATHOLOGY (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Elevated level of peripheral CD8+CD28- T lymphocytes are an independent predictor of progression-free survival in patients with metastatic breast cancer during the course of chemotherapy
Guohong Song et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Predictive value of peripheral blood lymphocyte count in breast cancer patients treated with primary chemotherapy
Maria Angeles Vicente Conesa et al.
BREAST (2012)
Investigation of NK cell function and their modulation in different malignancies
Gordana Konjevic et al.
IMMUNOLOGIC RESEARCH (2012)
Pathological Complete Response and Accelerated Drug Approval in Early Breast Cancer
Tatiana M. Prowell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity
Emilie Mamessier et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Ki67 in breast cancer: prognostic and predictive potential
Rinat Yerushalmi et al.
LANCET ONCOLOGY (2010)
Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
Priya Rastogi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Share Paper
